Cellivery Accelerates Clinical Trials for Sepsis Treatment New Drug... "Controls All Inflammatory Cytokines"

[Asia Economy Reporter Hyunseok Yoo] Cellivery announced on the 20th that its investigational drug for severe sepsis, iCP-NI, specifically controls the production of inflammatory cytokines inevitably accompanied by severe inflammation (such as pneumonia, hepatitis, enteritis) caused by various pathogenic bacteria and viral infections, thereby suppressing the cytokine storm as a treatment for severe inflammation.

Severe infectious inflammatory diseases that have occurred over the past 20 years, such as SARS, MERS, novel flu, avian influenza, and Ebola pandemics, commonly secrete large amounts of inflammatory cytokines that induce severe acute inflammation. This is called a cytokine storm. Blood vessels and tissues are destroyed, and vital organs such as the lungs and liver are damaged, leading to multiple organ failure, hypotension, and ultimately death.

Currently, vaccines and antibody developments are being attempted to neutralize the novel coronavirus infection (COVID-19). Antiviral antibody development is being pursued by inducing infected individuals to produce antibodies themselves through vaccines using attenuated viruses, or by mass-producing antibodies isolated from convalescent serum and injecting them into infected patients. A company official stated, "Even if research begins immediately after the outbreak of a viral infectious disease, the development speed is unlikely to catch up with the infection transmission speed," adding, "Even if development succeeds, it may be ineffective against new viruses caused by extreme viral mutations. Therefore, the development of severe inflammation treatments that can control cytokine storms caused by viral infections is urgently needed."

iCP-NI can treat severe sepsis by specifically controlling the production of all existing 20 types of inflammatory cytokines. Furthermore, the company explains that it can remarkably treat and protect against lung damage by suppressing pulmonary fibrosis, a hardening symptom in which the lungs become stiff and lose elasticity, a severe symptom of viral pneumonitis.

Daewoong Cho, CEO of Cellivery, said, "iCP-NI is a severe sepsis treatment drug that applies our platform technology TSDT to the cell-permeable inflammation-inhibiting peptide CP-NI, which I developed in the U.S. about 20 years ago as a bio-defense drug capable of rapid response to bio-terrorism and biochemical weapons, improving efficacy, stability, and safety," adding, "Safety and efficacy have been proven through over 1,000 animal experiments on hepatitis, peritonitis, and pneumonitis accumulated over the past 20 years of prior research and conducted at Cellivery."

He explained, "We will conduct the fastest track clinical trials such as priority review or fast track clinical applications with the U.S. FDA for confirmed COVID-19 patients by combining nonclinical data including safety derived domestically, and at the same time, we are strongly promoting joint clinical development with multinational big pharma partners of Cellivery."

This content was produced with the assistance of AI translation services.